<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; OncoGenex Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/oncogenex-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reported Loss Widens</title>
		<link>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669</link>
		<comments>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669#comments</comments>
		<pubDate>Mon, 09 May 2011 21:33:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73669</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents. Revenues came in at $21.1 million, well below the Zacks Consensus Estimate of $26 million. Lower revenues and higher operating expenses led to the wider first quarter 2011 loss. Quarter in Detail Revenues, which include license fees, milestone-related payments and other payments, declined 29.3% from the year-ago period during the first quarter of 2011. Isis Pharma earned a $750,000 milestone payment from OncoGenex (OGXI) on the initiation of a phase II study with OGX-427. First quarter revenues also included revenues recognized under the company’s collaboration agreement with GlaxoSmithKline (GSK). Isis Pharma could receive another ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceuticals Industries Oncology Drug Progresses</title>
		<link>http://www.stockbloghub.com/2010/10/05/teva-teva-pharmaceuticals-industries-oncology-drug-progresses/53966</link>
		<comments>http://www.stockbloghub.com/2010/10/05/teva-teva-pharmaceuticals-industries-oncology-drug-progresses/53966#comments</comments>
		<pubDate>Wed, 06 Oct 2010 03:45:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53966</guid>
		<description><![CDATA[Teva Pharmaceuticals Industries Ltd. (TEVA) and OncoGenex Pharmaceuticals, Inc. (OXGI) recently announced that they have initiated a second phase III study with their oncology candidate, custirsen (OGX-011/TV-1011). The trial, SYNERGY, will evaluate custirsen as a first-line treatment for patients suffering from metastatic castrate-resistant prostate cancer (CRPC). The controlled global study will be conducted with about 800 men who will be randomized to receive either docetaxel/prednisone plus custirsen or just docetaxel/prednisone. The primary endpoint is overall survival benefit. Custirsen is already in another phase III study that was initiated in June 2010. This study, SATURN, is evaluating custirsen as a second-line therapy in patients with metastatic CRPC. Both phase III studies are being conducted under the US Food and Drug Administration’s (FDA) Special Protocol Assessment (SPA) program. Custirsen enjoys fast track ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/05/teva-teva-pharmaceuticals-industries-oncology-drug-progresses/53966/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Expands Oncology Pipeline</title>
		<link>http://www.stockbloghub.com/2010/04/14/teva-teva-pharmaceutical-industries-expands-oncology-pipeline/33698</link>
		<comments>http://www.stockbloghub.com/2010/04/14/teva-teva-pharmaceutical-industries-expands-oncology-pipeline/33698#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:24:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33698</guid>
		<description><![CDATA[In a move to expand its branded product pipeline, generic player Teva Pharmaceutical Industries Ltd. (TEVA) recently entered into a research and exclusive license agreement with Mersana Therapeutics for the development and commercialization of oncology compound, XMT-1107. Mersana will be eligible to receive up to $334 million based on the achievement of development, regulatory and commercial milestones. Mersana is also entitled to receive royalties on product sales. Teva’s license for the candidate covers all indications including cancer and relates to all territories excluding Japan. Mersana intends to commence a phase I study with XMT-1107 in the second quarter of 2010. This deal is in-line with Teva’s goal to expand its innovative product pipeline. XMT-1107 is the second oncology candidate to be in-licensed by Teva over the past few months. In ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/teva-teva-pharmaceutical-industries-expands-oncology-pipeline/33698/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals&#8217; Loss Widens</title>
		<link>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550</link>
		<comments>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550#comments</comments>
		<pubDate>Wed, 03 Mar 2010 21:53:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29550</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 16 cents per share in the fourth quarter, which was wider than the Zacks Consensus Estimate of a net loss of 11 cents. The company had reported a net loss of 8 cents in the year ago period. The wider-than-expected loss was due to higher operating expenses. For the full year, the company reported a net loss of 31 cents, well above the net loss of 10 cents reported in 2008. Once again, higher operating expenses accounted for the wider loss despite an increase in revenues. Fourth quarter revenues increased 8.8% to $32.3 million. Revenues were boosted by a $10 million sublicensing fee earned by the company in December 2009 from OncoGenex Pharmaceuticals, Inc. (OGXI), which entered into a licensing agreement ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Gains from Teva-OncoGenex Deal</title>
		<link>http://www.stockbloghub.com/2009/12/29/isis-isis-pharmaceuticals-gains-from-teva-oncogenex-deal/23831</link>
		<comments>http://www.stockbloghub.com/2009/12/29/isis-isis-pharmaceuticals-gains-from-teva-oncogenex-deal/23831#comments</comments>
		<pubDate>Tue, 29 Dec 2009 19:06:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23831</guid>
		<description><![CDATA[Isis Pharmaceuticals, Inc. (ISIS) stands to benefit from the recently signed agreement between OncoGenex Pharmaceuticals (OGXI) and Teva Pharmaceutical Industries Ltd. (TEVA) for the development and commercialization of OGX-011. As Isis had co-discovered OGX-011 with OncoGenex, Isis is entitled to receive $10 million of the upfront payment made by Teva to OncoGenex. Isis will also receive 30% of the up to $370 million in milestone payments OncoGenex is eligible to receive, in addition to 5.5 &#8211; 7% royalties on all sales of OGX-011. OGX-011 is a second-generation antisense drug to inhibit cancer treatment resistance. The candidate is being developed for use as adjunct therapy to increase the effectiveness of chemotherapy. OGX-011 has completed phase II studies in prostate and lung cancer, and is scheduled to enter into two phase III ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/29/isis-isis-pharmaceuticals-gains-from-teva-oncogenex-deal/23831/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Expands Cancer Portfolio</title>
		<link>http://www.stockbloghub.com/2009/12/28/teva-teva-pharmaceutical-expands-cancer-portfolio/23739</link>
		<comments>http://www.stockbloghub.com/2009/12/28/teva-teva-pharmaceutical-expands-cancer-portfolio/23739#comments</comments>
		<pubDate>Tue, 29 Dec 2009 01:10:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23739</guid>
		<description><![CDATA[In a move to expand its branded product offering, generic player Teva Pharmaceutical Industries Ltd. (TEVA) recently entered into a global license and collaboration agreement with OncoGenex Pharmaceuticals, Inc. (OGXI). Teva and OncoGenex are collaborating for the development and commercialization of OncoGenex’ late stage pipeline candidate OGX-011 which is being studied for the treatment of different types of cancer. OGX-011 has been co-discovered with Isis Pharmaceuticals (ISIS) to inhibit cancer treatment resistance. The candidate is being developed for use as adjunct therapy to increase the effectiveness of chemotherapy. OGX-011 has completed phase II studies in prostate and lung cancer and is scheduled to enter into two phase III studies in 2010. While one study will be conducted to evaluate the candidate as second-line chemotherapy in men with metastatic castrate resistant ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/28/teva-teva-pharmaceutical-expands-cancer-portfolio/23739/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

